## Boston Scientific Receives Canadian License for its Carotid Wallstent® System

(February 19, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received a license for the sale of its Carotid Wallstent® Monorail® Endoprosthesis in Canada. The Company reported that Health Canada's Therapeutic Products Directorate, the authority that regulates pharmaceutical drugs and medical devices, licensed the use of all stent sizes of the Carotid Wallstent system. The Company said it plans to launch the product immediately in Canada.

"The Carotid Wallstent system represents a first-of-its-kind treatment option in Canada for carotid artery disease," said Paul LaViolette, Boston Scientific Senior Vice President and Group President, Cardiovascular. "This is an important step in our goal to make this important less-invasive procedure available to physicians and their patients worldwide."

The carotid arteries, located on either side of the neck, are the main conduits for blood flow to the brain. When narrowing occurs, patients become at risk for stroke. In Canada, approximately 200,000 people suffer annually from carotid artery disease.

The Carotid Wallstent Monorail Endoprosthesis is a self-expanding stent mounted on a rapid exchange deployment system, designed to open the carotid artery and improve blood flow to the brain. The device has been granted CE Mark and is commercially available in Europe and other international markets.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with commercialization of new technologies, clinical trials, regulatory approvals, competitive offerings, intellectual property, litigation, the Company's relationship with third parties, the Company's overall business strategy, and other factors described in the Company's filings with the Securities and Exchange Commission.

https://news.bostonscientific.com/news-releases?item=58802